4D Molecular Therapeutics, Inc. Common Stock
$13.76
$0.13 (+0.95%)
$13.54Day Range$14.20
Key Statistics
Market Cap
$752.98M
Shares Outstanding
55.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 11, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$13.65
Day High
$14.20
Day Low
$13.54
Volume
819.6K
VWAP
$13.81
Prev Close
$13.63
Transactions
--
Acc. Volume
--
About 4D Molecular Therapeutics, Inc. Common Stock
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836196 employees5858 HORTON STREET #455, EMERYVILLE, CA, 94608(510) 505-2680IPO Dec 11, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001650648
- Composite FIGI
- BBG00QG40R88
- Share Class FIGI
- BBG00QG40S04
- Ticker Root
- FDMT
- SIC Code
- 2836
About 4D Molecular Therapeutics, Inc. Common Stock (FDMT) Stock
4D Molecular Therapeutics, Inc. Common Stock (FDMT) closed the 2026-09-16 session at $13.76, up 0.95% versus the previous close (+0.13). The stock opened at $13.65 and traded between $13.54 and $14.20 during that session. Session trading volume was 820K shares. The volume-weighted average price (VWAP) is $13.81.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
4D Molecular Therapeutics, Inc. Common Stock has a market capitalization of $753.0 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. FDMT is listed on the XNAS exchange. The company employs approximately 196 people. 4D Molecular Therapeutics, Inc. Common Stock is headquartered in EMERYVILLE, CA. The recorded listing date is 2020-12-11.
On this page you can find market FDMT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.